Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer [PLANE-PC]
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Neuroendocrine Tumors
- Prostate Cancer Metastatic
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04848337
- Collaborators
- Merck Sharp & Dohme Corp.
- University of Michigan
- Investigators
- Principal Investigator: Ulka Vaishampayan, MD University of Michigan
Get Well Soon